Researchers compare the impacts of cART by itself versus cART plus the IDO inhibitor in lung tissue of nonhuman primates with both TB and SIV. Left: Following just cART, significantly more IDO is ...

Researchers from the faculty of medicine at the University of Ottawa and their international collaborators say they have shown proof-of-concept for a new therapeutic approach in treating tuberculosis ...

A recent study published by researchers at Baylor College of Medicine and Texas Children’s Hospital, in collaboration with the German Center for Infection Research, identified two main subtypes or ...

The immune system remains seriously out-of-whack – in an inflammatory state of overactivation and impaired functionality – ...

One of the main challenges for tuberculosis (TB) therapy is how to deliver drugs to the site of disease. Once the body’s immune system is infected with tuberculosis, it forms granulomas—tight clusters ...

A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB). Scientists at Texas Biomedical Research Institute ...

The results of three randomized, controlled trials (SAPiT, STRIDE, and CAMELIA) demonstrate that, for coinfected patients with advanced immunosuppression, the survival benefit of starting ART within ...

TB remains the leading cause of death among people living with HIV. Uganda is a high TB-burden country, and HIV accelerates ...

Simple markers of anemia and systemic inflammation may be important tools for identifying patients with human immunodeficiency virus (HIV) infection who are at higher risk for active tuberculosis (TB) ...

A therapy showing promise to help control tuberculosis does not interfere with combined antiretroviral therapy (cART), according to new research. A therapy showing promise to help control tuberculosis ...